What question did this study set out to answer?

The research aims to clarify the interactions of ribociclib with OATP1B and its implications for drug co-administration.

April 10, 2026Open Access

Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo

Key Points

The research aims to clarify the interactions of ribociclib with OATP1B and its implications for drug co-administration.
Conducted in vivo analysis of ribociclib's effects on OATP1B
Evaluated ribociclib as a substrate and inhibitor of OATP1B
Examined potential clinically significant interactions
Ribociclib does not act as a substrate for OATP1B
Ribociclib does not inhibit OATP1B-mediated uptake
No anticipated significant drug interactions with OATP1B

Abstract

Our findings suggest that clinically significant OATP1B-mediated interactions are not anticipated with CDK4/6 inhibitors, either as victims or perpetrators, which supports ongoing clinical trials investigating the co-administration of CDK4/6 inhibitors with OATP1B substrates and inhibitors.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Thomas Drabison

E. H. Ahmed

Nathan Colasanti

Journals

Cancer Chemotherapy and Pharmacology

Actions

Institutions

The Ohio State University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider